



US009408844B2

(12) **United States Patent**
Reaume et al.

(10) **Patent No.:** **US 9,408,844 B2**
(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **METHODS FOR TREATING
INFLAMMATORY CONDITIONS**

(71) Applicant: **Melior Discovery, Inc.**, Exton, PA (US)

(72) Inventors: **Andrew Reaume**, Exton, PA (US);
Heather Hain, Exton, PA (US); **Michael
S. Saporito**, Exton, PA (US)

(73) Assignee: **Melior Discovery, Inc.**, Exton, PA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **14/254,947**

(22) Filed: **Apr. 17, 2014**

(65) **Prior Publication Data**

US 2014/0227209 A1 Aug. 14, 2014

Related U.S. Application Data

(63) Continuation of application No. 11/937,680, filed on
Nov. 9, 2007, now Pat. No. 8,716,294.

(60) Provisional application No. 60/865,315, filed on Nov.
10, 2006.

(51) **Int. Cl.**

A61K 31/497 (2006.01)

A61K 31/496 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/496** (2013.01); **A61K 31/497**
(2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,608,094 B2 8/2003 Sankaranarayanan

FOREIGN PATENT DOCUMENTS

WO 2006072175 A1 7/2006

WO 2008101692 A1 8/2008

OTHER PUBLICATIONS

Black et al (BMC Pulmonary Med 4:1-7, 2004).*

Shoda et al (Endocrinology 138:1886-1892, 1997).*

Campo et al., Expression of Receptor for Advanced Glycation End Products in Sarcoid Granulomas, Am J Respir Crit Care Med, (2007), 175:498-506.

Colaco et al., The role of the Maillard reaction in other pathologies: Alzheimer's disease, Nephrol Dial Transplant, (1996), 11(Suppl 5):7-12. Abstract only.

Dierks et al., Influence of Tenilsetam on AEP-P300 in Alzheimer's disease, J Neural Transm, (1989), [P-D Sect], 1:49.

Hinshaw et al., Hypersensitivity Reactions, Delayed—http://emedicine.medscape.com (Mortality/Morbidity Section, viewed online Jul. 30, 2009.

Münch et al., The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation, J Neural Transm, (1994), [P-D Sect], 8(3):193-208.

Nakamura et al., Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock, Pharm Res, (2009).

Reddy et al., Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases, Drug Discov Today, (Jul. 2006), 11(13-14):646-654. Abstract only.

Sander et al., Oxidative Stress, Irritant Dermatitis, (2006), Ch 40: 375-382.

Senaldi et al., Protective Effect of N-Acetylcysteine in Hapten-Induced Irritant and Contact Hypersensitivity Reactions, J Invest Dermatol, (1994), 102:934-937.

Shoda et al., Inhibitory Effects of Tenilsetam on the Maillard Reaction, Endocrinology, (May 1997), 138(5):1885-1895.

The Merriam Webster Online Dictionary (accessed online on Jul. 30, 2009).

Tsukahara et al., High Levels of Urinary Pentosidine, an Advanced Glycation End Product, in Children With Acute Exacerbation of Atopic Dermatitis: Relationship With Oxidative Stress, Metabolism, (2003), 52(12):1601-1605.

Aisen et al., Inflammation and Alzheimer disease, Mol Chem Neuropathol, (May-Aug. 1996), 28(1-3):83-88.

* cited by examiner

Primary Examiner — Craig Ricci

(74) *Attorney, Agent, or Firm* — Pepper Hamilton LLP

(57) **ABSTRACT**

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.

23 Claims, 3 Drawing Sheets